GKB Ophthalmics

Why is GKB Ophthalmics Ltd falling/rising?

As of 06-Jul, GKB Ophthalmics Ltd's stock price is Rs 60.35, down 4.37%, with significant underperformance over the past week and month compared to the Sensex. The stock is trading below all major moving averages and has seen a drastic drop in investor participation.

As of 06-Jul, GKB Ophthalmics Ltd is experiencing a decline in its stock price, currently at Rs 60.35, which represents a change of -2.76 (-4.37%). This downward movement is reflected in various performance metrics. Over the past week, the stock has underperformed significantly, with a decrease of -3.67%, while the benchmark Sensex has increased by +2.03%. In the last month, the stock has also fallen by -2.66%, contrasting with a +5.44% rise in the Sensex.<BR><BR>Today's trading session has seen the stock open with a loss of -3.87% and reach an intraday low of Rs 60, marking a decline of -4.93%. Additionally, GKB Ophthalmics is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish trend. The stock has also seen a significant drop in investor participation, with delivery volume falling by -95.7% against the 5-day average, suggesting reduced interest from investors. Overall, these factors contribute to the stock's current decline.

Which are the latest news on GKB Ophthalmics?

Should I buy, sell or hold GKB Ophthalmics Ltd?

How big is GKB Ophthalmics?

As of 10th June, GKB Ophthalmics Ltd has a market capitalization of 32.00 Cr, with recent net sales of 149.06 Cr and a net profit of 1.21 Cr.

As of 10th June, GKB Ophthalmics Ltd has a market capitalization of 32.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, GKB Ophthalmics reported Net Sales of 149.06 Cr and a Net Profit of 1.21 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 52.04 Cr and Total Assets of 125.21 Cr.

Who are in the management team of GKB Ophthalmics?

The management team of GKB Ophthalmics includes K G Gupta (Chairman/Executive Director), Vikram Gupta (Non-Executive Director), Subhash Redkar (Executive Director), and three Independent Non-Executive Directors: Anil Palekar, Shashi Kumar Katreddi, and Purushottam Mantri.

The management team of GKB Ophthalmics includes the following individuals:<BR><BR>1. K G Gupta - Chairman / Executive Director<BR>2. Vikram Gupta - Non Executive Director<BR>3. Subhash Redkar - Executive Director<BR>4. Anil Palekar - Independent Non Executive Director<BR>5. Shashi Kumar Katreddi - Independent Non Executive Director<BR>6. Purushottam Mantri - Independent Non Executive Director<BR><BR>If you need more information about their roles or the company, feel free to ask!

Who are the peers of the GKB Ophthalmics?

GKB Ophthalmics' peers include Bandaram Pharma, Amkay Products, KMS Medisurgi, N G Industries, and others. In terms of management risk, growth, and returns, GKB Ophthalmics shows below-average management risk and good growth, with a 1-year return of -22.24%.

Peers: The peers of GKB Ophthalmics are Bandaram Pharma, Amkay Products, KMS Medisurgi, N G Industries, Samsrita Labs, Deccan Healthcar, Centenial Surgic, Chennai Meena, and Tejnaksh Health.<BR><BR>Quality Snapshot: Excellent management risk is observed at Amkay Products and N G Industries, while Average management risk is found at KMS Medisurgi. Below Average management risk is noted at Bandaram Pharma, Deccan Healthcar, GKB Ophthalmics, Centenial Surgic, and Tejnaksh Health, and the rest. Growth is rated as Excellent at Amkay Products, while Good growth is seen at Bandaram Pharma, Deccan Healthcar, and GKB Ophthalmics, with the rest showing Below Average growth. Capital Structure is rated as Good for Amkay Products, KMS Medisurgi, N G Industries, Deccan Healthcar, and GKB Ophthalmics, while Below Average is noted for Bandaram Pharma, Centenial Surgic, and Tejnaksh Health, and the rest have an Average rating.<BR><BR>Return Snapshot: Amkay Products has the highest 1-year return at 28.21%, while Deccan Healthcar has the lowest at -39.81%. GKB Ophthalmics' 1-year return is -22.24%, which is better than Deccan Healthcar but worse than Amkay Products. Additionally, several peers, including Deccan Healthcar, Centenial Surgic, and Tejnaksh Health, have negative six-month returns.

What does GKB Ophthalmics do?

GKB Ophthalmics Ltd is a micro-cap healthcare services company, incorporated in 1981, specializing in ophthalmic products with a market cap of INR 32 Cr. As of March 2026, it reported net sales of 30 Cr and a net profit of 0 Cr.

Overview:<BR>GKB Ophthalmics Ltd operates in the healthcare services industry as a micro-cap company.<BR><BR>History:<BR>Incorporated in December 1981, GKB Ophthalmics was granted a license as a 100% Export Oriented Unit (EOU) in 1982. The company reported net sales and net profit for the quarter ending March 2026.<BR><BR>Financial Snapshot:<BR>Net Sales: 30 Cr (Quarterly Results - Mar 2026) <BR>Net Profit: 0 Cr (Quarterly Results - Mar 2026) <BR>Market cap: INR 32 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 10.00 <BR>Industry P/E: 45 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.13 <BR>Return on Equity: 5.68% <BR>Price to Book: 0.60 <BR><BR>Contact Details:<BR>Address: 16-A, Tivim Industrial Estate Mapusa Goa : 403526 <BR>Tel: 91-832-2257253/6714444 <BR>Email: investor.grievance@gkb.net <BR>Website: http://www.gkb.net

Are GKB Ophthalmics Ltd latest results good or bad?

GKB Ophthalmics Ltd's latest results are considered bad, with a significant decline in net profit and sales, leading to a 4.62% drop in stock price. The company faces operational challenges, reflected in its "RISKY" valuation and "BELOW AVERAGE" quality grade.

The latest results for GKB Ophthalmics Ltd indicate a challenging situation for the company. The stock has underperformed significantly, declining 4.62% to ₹62.00 following the results announcement, and it has a year-to-date decline of 15.07%, which is worse than the Sensex's 7.00% fall over the same period.<BR><BR>In terms of financial performance, the company reported a consolidated net profit of ₹0.19 crore for Q4 FY26, which represents a sharp decline of 56.82% quarter-on-quarter and a staggering 105.35% drop year-on-year. Net sales also fell dramatically to ₹29.79 crore, marking a 47.54% decrease from the previous quarter and a 3.97% decline year-on-year. This is particularly concerning as it reflects the lowest quarterly revenue in the last seven quarters.<BR><BR>While there were some positive signs, such as an improvement in the operating margin to 10.44%, this was overshadowed by the significant drop in revenue and profits. Analysts have classified the company's valuation as "RISKY," and its quality grade is "BELOW AVERAGE," suggesting that there are fundamental challenges that need to be addressed.<BR><BR>Overall, the results can be considered bad, highlighting operational difficulties and raising concerns about the company's ability to sustain profitability and growth in the future.

How has been the historical performance of GKB Ophthalmics?

GKB Ophthalmics has seen revenue growth from INR 56.88 crore in March 2021 to INR 108.99 crore in March 2025, but has faced significant operating losses and negative cash flow, resulting in a profit after tax loss of -INR 7.26 crore in March 2025. Despite increasing total assets, the company's profitability has declined sharply in recent periods.

Answer:<BR>The historical performance of GKB Ophthalmics shows a fluctuating trend in revenue and profitability over the years, with significant losses reported in recent periods.<BR><BR>Breakdown:<BR>GKB Ophthalmics has experienced a steady increase in net sales from INR 56.88 crore in March 2021 to INR 108.99 crore in March 2025. However, the company has faced rising total expenditures, which grew from INR 54.96 crore in March 2021 to INR 111.77 crore in March 2025, leading to operating losses. Operating profit (PBDIT) turned negative in March 2025 at -INR 1.45 crore, down from a positive INR 4.60 crore in March 2023. Profit before tax also declined significantly, reaching -INR 6.91 crore in March 2025, compared to a profit of INR 0.11 crore in March 2023. Consequently, the profit after tax showed a similar downward trend, resulting in a loss of -INR 7.26 crore in March 2025, compared to a small profit of INR 0.08 crore in March 2023. The company's total assets increased from INR 102.25 crore in March 2020 to INR 125.21 crore in March 2025, while total liabilities also rose from INR 102.25 crore to INR 125.21 crore during the same period. Cash flow from operating activities has been negative in the latest year at -INR 3.00 crore, indicating challenges in generating cash from core operations. Overall, GKB Ophthalmics has shown growth in sales but has struggled with profitability and cash flow in recent years.

When is the next results date for GKB Ophthalmics?

GKB Ophthalmics will announce its results on 14 August 2025.

GKB Ophthalmics will declare its results on 14 August 2025.

Who are the top shareholders of the GKB Ophthalmics?

The top shareholders of GKB Ophthalmics include promoter Krishna Gopal Gupta with 17.91%, public shareholder Krishna Murari Gupta at 5.54%, and individual investors holding 37.36%. There are no pledged promoter holdings or mutual funds invested in the company.

The top shareholders of GKB Ophthalmics include the promoters, with Krishna Gopal Gupta holding the largest share at 17.91%. The highest public shareholder is Krishna Murari Gupta, who holds 5.54%. Additionally, individual investors collectively hold 37.36% of the company's shares. There is also one foreign institutional investor (FII) that holds 1.79% of the shares. Notably, there are no pledged promoter holdings and no mutual funds currently invested in the company.

Is GKB Ophthalmics overvalued or undervalued?

As of August 14, 2023, GKB Ophthalmics is considered undervalued with a risky valuation grade, reflected by its negative PE ratio of -5.36 and EV to EBITDA of -13.84, especially when compared to peers like Hindustan Unilever and Nestle India, and its stock has underperformed the Sensex with a year-to-date return of -24.04%.

As of 14 August 2023, the valuation grade for GKB Ophthalmics has moved from very expensive to risky, indicating a significant shift in its perceived value. The company is currently considered undervalued, particularly given its negative PE ratio of -5.36 and an EV to EBITDA ratio of -13.84, which highlight substantial financial distress. Additionally, the Price to Book Value stands at 0.73, suggesting that the market values the company below its book value.<BR><BR>In comparison to its peers, GKB Ophthalmics shows stark contrasts; for instance, Hindustan Unilever has a PE ratio of 53.88 and an EV to EBITDA of 37.14, while Nestle India exhibits even higher figures with a PE of 75.2 and an EV to EBITDA of 49.57. These comparisons underscore the challenges faced by GKB Ophthalmics, as it operates in a sector where competitors are significantly more valued. Furthermore, the company's recent stock performance has lagged behind the Sensex, with a year-to-date return of -24.04% compared to the Sensex's 5.63%, reinforcing the notion of its undervaluation amidst broader market trends.

What is the technical trend for GKB Ophthalmics?

As of May 23, 2025, GKB Ophthalmics is in a mildly bearish trend, with daily moving averages and Bollinger Bands indicating bearish conditions, despite some mildly bullish signals from the MACD and Dow Theory.

As of 23 May 2025, the technical trend for GKB Ophthalmics has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by the daily moving averages indicating a bearish trend and the Bollinger Bands showing bearish conditions on both weekly and monthly time frames. The MACD on a weekly basis is mildly bullish, which contrasts with the monthly bearish signal, while the RSI shows no signal on the weekly but is bullish on the monthly. Dow Theory supports a mildly bullish stance on both weekly and monthly time frames, but overall, the bearish indicators dominate the current outlook.

Has GKB Ophthalmics declared dividend?

GKB Ophthalmics Ltd has declared a 12% dividend, amounting to 1.2000 per share, with an ex-date of September 21, 2010. However, total returns over various periods show negative performance in the short term, and the dividend yield is 0%, indicating minimal impact on shareholder returns.

GKB Ophthalmics Ltd has declared a 12% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 12%<BR>- Amount per share: 1.2000<BR>- Ex-date: Sep-21-2010<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>Over the 6-month period, the price return was -24.87%, the dividend return was 0%, resulting in a total return of -24.87%.<BR><BR>For the 1-year period, the price return was -13.74%, the dividend return was 0%, leading to a total return of -13.74%.<BR><BR>In the 2-year period, the price return was -15.2%, the dividend return was 0%, which resulted in a total return of -15.2%.<BR><BR>During the 3-year period, the price return was 0%, the dividend return was 0%, yielding a total return of 0.0%.<BR><BR>For the 4-year period, the price return was 12.49%, the dividend return was 0%, culminating in a total return of 12.49%.<BR><BR>In the 5-year period, the price return was 23.2%, the dividend return was 0%, resulting in a total return of 23.2%.<BR><BR>Overall, while GKB Ophthalmics Ltd has declared a dividend, the total returns over various periods indicate a negative performance in the short term, with only modest gains in the longer term. The absence of dividend yield suggests that the declared dividend has not significantly impacted shareholder returns.